Johnson Winter Slattery (JWS) has advised SV Health Investors, Sanofi Ventures and Abingworth as three out of the four co-lead investors on the US$112 million Series C financing of AdvanCell. AdvanCell is an Australian clinical-stage radiopharmaceutical company developing innovative cancer therapeutics.
JWS advised SV Health Investors, Sanofi Ventures and Abingworth on the Series C financing process, including transaction structuring, due diligence, negotiation, and preparation of all transaction documents. JWS worked alongside the Honigman team in the US.
Partner Clare Brown led the JWS team, supported by Senior Associate Nick Haenel and associates James Antonenas, Joshua Chin and Gabriele Santoro.
Clare Brown said, “We are pleased to have assisted SV Health Investors, Sanofi Ventures and Abingworth in leading this successful Series C financing. The financing is a significant milestone for AdvanCell and we look forward to seeing the company continue its journey to transform cancer care.”
Details of the Series C financing were published in Business Wire.
About Johnson Winter Slattery
JWS is a leading Australian law firm known for advising corporates and funds on their most complex transactions, disputes and regulatory matters. The firm is comprised of more than 450 people, including 85+ partners, across Sydney, Melbourne, Adelaide, Canberra, Brisbane and Perth.
Media contacts
Angela Welsh, Marketing & Communications Manager
T: +61 2 9392 7454 | M: +61 414 281 902
E: angela.welsh@jws.com.au
Maureen Grose, Marketing & Business Development Director
T: +61 2 8247 9697 | M: +61 447 004 445
E: maureen.grose@jws.com.au
